News

Analysis shows breast cancer was the most extensively studied disease area in previous year.

Expands drug development and FDA regulatory expertise.

Deal takes the Phastar group to around 550 people worldwide and strengthens the company's position in Nordic region.

Combined Pinnacle and STRI platform expands network to six stand-alone sites.

Collaboration will aim to improve patient identification, stratification, recruitment, and enrollment in rare disease trials.

Company provides startup biotechs access to collaboration platform for a year.

Transaction gives NEUCA Group a 72.6% stake in OncoBay.

Partnership aims to accelerate discovery of treatments for rare diseases.

Study finds that digital maturity, capability prioritization, and best practice adoption vary widely.

The latest industry happenings, all in one place.

New collaboration leverages MyEyeDr.’s offices across the US to refer patients into ophthalmology and other therapeutic area clinical trials, expands Parexel’s Community Alliance Network to bring trials to patients where they are.

Strong shift to DCTs, regulatory changes, and increased focus on diversity among main industry talking points in 2022.

Targeted program aims to identify and accelerate novel oncology innovations into commercially-attractive assets.

Kenneth Koblan, PhD, chief scientific officer at Sunovion, discusses novel therapy development and clinical trial challenges in mental health.

Partnership will allow providers to recommend clinical trials as a therapeutic option at the point-of-care using IllumiCare's Trials App.

Partnership started in April 2021 will continue to advance clinical trials through DCT solutions.

Partnership will leverage Acclinate's NOWINCLUDED™ community through Trialbee Honey™ Omnichannel.

Addition of Complion's eReg offering adds another product to RealTime's site operations management system.

New center will focus on the clinical trials of clients who are developing cell and gene therapies across multiple therapeutic areas.

Functionality seeks to alleviate eCOA burdens, reduce time-to-launch, and improve site, clinician, and patient experience.

How streamlining relations between central labs and mobile health providers can get the most from hybrid and DCTs.

Designed with customer and patient feedback to expand options for eCOA and other DCT activities.

Study shows eCOA/ePRO interface is equivalent to responses from text-based smartphone formats.

Tufts CSDD report based on data collected and analyzed financial, personnel, and trend data from 18 top public and private CROs.

New pro-bono offering allows charities to access PHASTAR’s biometrics experts at no cost.

Think tank and survey results inform current DCT landscape.

Recent investments bring clinical trial technology platform to the fore.

Nabil Chehab, medical affairs head of lung cancer franchise at AstraZeneca, discuss strategies used in the Phase III AEGEAN trial for treating non-small lung cancer (NSCLC).